The UK's Prescription Medicines Code of Practice Authority (PMCPA) has issued a stinging rebuke to GSK, ruling that the company showed a "totally unacceptable" lack of transparency in its interactions with the regulator. The self-regulatory body also characterized GSK's behavior as "grossly misleading," according to a report from Fierce Pharma.
The ruling centers on how GSK handled communications with the PMCPA, though the specific product or context is not detailed in the source. The PMCPA's decision highlights a failure to meet the standards expected of pharmaceutical companies operating under the UK's voluntary code of practice.
This is not the first time GSK has faced regulatory scrutiny, but the strength of the language used by the PMCPA underscores the seriousness of the breach. The company has not yet issued a public response in the source material, and no further details about potential sanctions or next steps were provided.